Skip to main
NRXP
NRXP logo

NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals (NRXP) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NRX Pharmaceuticals Inc has significantly bolstered its financial position through recent financing activities, enhancing its cash reserves to advance its clinical development and commercialization efforts. The company has expressed confidence in achieving profitability on a run-rate basis by the end of 2025, supported by strategic partnerships and the acquisition of revenue-generating entities, including the anticipated $10 million annual revenue from recent acquisitions. Additionally, NRX-101's demonstrated efficacy in treating bipolar depression with acute suicidal ideation, along with its expanding clinical pipeline and targeted revenue goal of $100 million by 2025, contributes to a favorable outlook for the company's stock.

Bears say

NRX Pharmaceuticals Inc. is projected to significantly reduce its annual operating loss from $27.8 million in 2023 to $18.5 million in 2024, largely attributed to decreased research and development spending. Key risks affecting the company's outlook include the potential failure of ongoing clinical trials, stringent regulatory obligations, and challenges related to product commercialization and market differentiation. Additionally, the company faces uncertainties regarding intellectual property protection and the challenges posed by potential fundraising in unfavorable market conditions.

NRX Pharmaceuticals (NRXP) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NRX Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NRX Pharmaceuticals (NRXP) Forecast

Analysts have given NRX Pharmaceuticals (NRXP) a Strong Buy based on their latest research and market trends.

According to 5 analysts, NRX Pharmaceuticals (NRXP) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NRX Pharmaceuticals (NRXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.